Australia markets open in 1 hour 45 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
25.45+0.18 (+0.71%)
At close: 04:00PM EST
25.45 0.00 (0.00%)
After hours: 04:01PM EST

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270

Full-time employees299

Key executives

NameTitlePayExercisedYear born
Dr. Joseph K. Belanoff M.D.Co-Founder, President, CEO & Director1.82M19.31M1957
Mr. Atabak MokariCFO & Treasurer760.75kN/A1977
Dr. Hazel Hunt Ph.D.Chief Scientific Officer895.16k1.75M1960
Mr. Sean MaduckPresident of Corcept Endocrinology823.42k3.37M1977
Mr. Gary Charles RobbChief Business Officer & Secretary963k4.82M1963
Mr. Joseph Douglas LyonChief Accounting OfficerN/AN/A1979
Ms. Amy FloodChief Human Resources & Communications OfficerN/AN/AN/A
Dr. William Guyer Pharm.D.Chief Development OfficerN/AN/A1968
Ms. Monica TelladoPresident of Emerging MarketsN/AN/A1973
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe metabolic, oncologic, endocrine, and neurological disorders in the United States. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. It is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corporate governance

Corcept Therapeutics Incorporated’s ISS governance QualityScore as of 28 November 2023 is 6. The pillar scores are Audit: 4; Board: 4; Shareholder rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.